Clinical trial NCT06282133: Behavioural Experiments for Generalized Anxiety in Adolescents - Pilot Study
Official title: Behavioural Experiments for Intolerance of Uncertainty: A Novel Treatment for Generalized Anxiety Disorder in Adolescents - A Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Generalized Anxiety Disorder
Adolescent - Emotional Problem
Keywords: Cognitive-behavioural therapy
Lead sponsor: Universite du Quebec en Outaouais
Sponsor class: OTHER
First posted: 2024-02-28
Enrollment: 8
Sex: ALL
Minimum age (years): 14
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Open trial
Primary purpose: TREATMENT

Brief summary: Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry and anxiety. In adolescents, this condition can seriously impact their development, academic performance, and social relationships. In Canada, 3 to 4% of the population (between 0.9% and 2.7% among adolescents) suffers from GAD at any given time in their lives. These young individuals experience a reduced quality of life and are at risk for numerous medical conditions, as well as additional psychological issues. Research suggests that both pharmacological and psychological approaches are effective in treating GAD in the short term. However, psychological treatments appear to offer the greatest long-term benefits. There are a number of effective psychological treatments for GAD, most of which fall under cognitive-behavioural therapy (CBT) adapted for this age group.

In the 1990s, a group of Canadian researchers developed a CBT protocol for GAD that included four components. Data from six clinical trials in adults suggest that one of the four components is particularly important for treatment success: exposing oneself to uncertainty rather than avoiding it in daily life. In other words, learning to tolerate and manage uncertainty seems to be the key to reducing worry and anxiety.

Given this discovery, researchers developed a new treatment that exclusively targets intolerance to uncertainty and then adapted it for adolescents: Behavioural Experiments for Intolerance to Uncertainty in Adolescents (EC-IIA). The aim of the current pilot study is to test the effectiveness of EC-IIA in adolescent individuals. A total of 8 participants with a primary diagnosis of GAD will receive EC-IIA and will be evaluated at 4 different times ranging from pre-treatment to a 6-month follow-up. Conditions will be compared in terms of treatment efficacy and mechanisms. Researchers will also examine predictors of change during the 6 months following treatment. The proposed study will produce data on the effectiveness and mechanisms of a treatment for GAD that is less costly, less complex, and easier to disseminate than currently available treatments.


Eligibility criteria: Inclusion Criteria:

Adolescents aged between 14 and 18 years; 2) primary diagnosis of Generalized Anxiety Disorder (GAD); 3) no change in type or dose of medication in the 4 to 12 weeks preceding entry into the study (4 weeks for benzodiazepines, 12 weeks for antidepressants, hypnotics, and psychostimulants); 4) willingness to maintain stable medication status during participation in the study; 5) absence of consumption of herbal products known to have effects on the central nervous system in the 2 weeks preceding entry into the study; 6) absence of evidence of suicidal intent (based on clinical judgment); 7) absence of evidence of current substance use, current or past schizophrenia, bipolar disorder, or organic mental disorder; 8) absence of current participation in other clinical trials (i.e., psychotherapeutic services); 9) absence of concurrent psychotherapy during the trial treatment phase; 10) absence of evidence of anxiety symptoms due to a general medical condition based on clinical judgment (e.g., clinical hyperthyroidism, hypoglycemia, anemia).

Primary outcomes:
measure: Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5)
timeFrame: 10 weeks
Secondary outcomes:
measure: Worry and Anxiety Questionnaire (WAQ)
timeFrame: 10 weeks
measure: Penn State Worry Questionnaire (PSWQ)
timeFrame: 10 weeks
measure: Beck Anxiety Inventory (BAI)
timeFrame: 10 weeks
measure: Beck Depression Inventory-II (BDI-II)
timeFrame: 10 weeks
Other outcomes:
measure: Intolerance of Uncertainty Scale (IUS)
timeFrame: 10 weeks
measure: Safety Behaviors Questionnaire (SBQ)
timeFrame: 10 weeks
measure: Treatment Acceptance and Adherence Scale (TAAS)
timeFrame: 3 weeks
measure: Working Alliance Inventory (WAI)
timeFrame: 3 weeks
Locations:
city: Gatineau
country: Canada
facility: Universite du Quebec en Outaouais
state: Quebec
Study officials:
affiliation: Universite du Quebec en Outaouais
name: Michel J. Dugas, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: